Dose Rounding for Systemic Therapy
Customize your policy alerts
Sign up for Aloha Care Policy RXMP-36 alerts
Get alerted when Policy RXMP-36 changes without checking for updates manually.
Monitor payer policy activity
Defines AlohaCare's policy to implement dose rounding for select systemic cancer therapies (injectable and oral) to reduce waste and cost, affecting providers submitting prior authorizations and administering cancer drugs under pharmacy and medical benefits.
No material clinical or coverage changes in this revision.
Coverage Criteria — Dose Rounding
When dose rounding is applied
Dose rounding is applied when ALL of the following are met
If the provider accepts the rounded dose in MBMNow, the authorization may be auto-approved and include total approved billable units for the course of treatment.
Dose rounding is not applied when rounding down will not result in using fewer vials, capsules, or tablets per treatment. The policy applies rounding only when a reduced dose (within the allowed tolerance) meaningfully decreases the number of single‑use vials or oral dosage units needed for that administration; if no reduction in vial or unit count occurs, do not round the dose.
This guidance is informational and does not constitute medical advice. Providers must exercise independent clinical judgment and make treatment decisions in consultation with the patient; acceptance of a rounded dose is voluntary and is not required to obtain prior authorization.
Coding and Tolerances
| J0893 | Decitabine (sun pharma) |
| J0893 | (also listed mapping: HCPCS Code = J9294 in source) |
| J0894 | Decitabine (Dacogen®) |
| J0894 | (also listed mapping: HCPCS Code = J9296 in source) |
| J9025 | Azacitidine (Vidaza®) |
| J9025 | (also listed mapping: HCPCS Code = J9297 in source) |
| J9033 | Bendamustine (Treanda®) |
| J9033 | (also listed mapping: HCPCS Code = J9299 in source) |
| J9035 | Bevacizumab (Avastin®) |
| J9035 | (also listed mapping: HCPCS Code = J9303 in source) |
Provider Actions and Prior Authorization
Prior authorization processing via MBMNow — Optum CGP calculates rounding candidates
When a prior authorization is submitted through MBMNow, Optum's Cancer Guidance Program automatically determines cases where dose rounding applies and calculates the per-treatment dosage based on the patient's height and/or weight and the NCCN-recommended dosage. If the provider accepts the rounded dose when offered in MBMNow, the request may be automatically approved and the authorization will include the total approved billable units for the course of treatment based on the rounded dose and approved cycles.
- Automatic identification of rounding candidates and dose calculation performed by Optum CGP in MBMNow
- Auto-approval possible if provider accepts the rounded dose; authorization will include total approved billable units for the course of treatment
Step therapy — none specified
This guideline specifies no step therapy requirements for dose rounding; there are no additional required prior treatment steps outlined.
Submission and reauthorization — MBMNow submission; reauth for ≥10% weight change
Providers must submit prior authorization requests through MBMNow; Optum's Cancer Guidance Program will calculate rounded doses. If a member's weight changes significantly (>=10%) during therapy, a new authorization must be submitted to ensure the total authorized dose is not exceeded.
- Submit initial and follow-up prior authorizations via MBMNow
- Reauthorization required when member weight changes >=10% during the course of therapy
Custom review required if rounded dose is declined
If the Optum Cancer Guidance Program offers a rounded dose in MBMNow and the provider declines the rounded dose, the prior authorization request will require custom review and a Cancer Guidance Program Nurse may contact the provider for additional information.
- Declining the rounded dose prevents auto-approval and triggers custom review and possible outreach
Background and Purpose
Dose rounding is intended to reduce drug waste and associated costs while preserving clinical efficacy. The goals include reducing single‑use vial waste, minimizing unnecessary handling and exposure for health care personnel, and lowering overall treatment costs when a rounded dose (within policy tolerance) can be used without compromising efficacy. This policy aligns with referenced guidance (NCCN/HOPA/ASCO) and is implemented for select systemic cancer therapies through the Cancer Guidance Program.
Definitions
Revision History
Policy revised and updated; Review/Revision date 2025-09-11 reflecting adoption of Optum Cancer Guidance Program dose rounding and related details (effective date set 2026-01-01).
Policy effective date set to 2026-01-01 as specified in the policy header.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.